August 4, 2020
Researchers Optimistic After Dose-Determining Trial of Compound Against Metastatic Castration-Resistant Prostate Cancer
Joshi Alumkal, MD finds good tolerability and encouraging efficacy data for the pan-BET bromodomain inhibitor in combination with enzalutamide.